The EU Project

ePrescription and Automation for a Safe Management of Cytostatics

In the critical area of cancer care, healthcare providers are experiencing a growing pressure to improve patient safety and decrease operators’ risk, while at the same time working more efficiently and containing costs.

The compounding of oncology drugs – cytostatics – is a particularly challenging area, because of the following factors:

• high potential for adverse drug events, due to the narrow window between toxic an therapeutic effect;
• significant occupational risk, due to the exposure to toxic drugs during compounding and aministration;
• rocketing drug budgets, due to growing cancer rates and marketing of new, expensive drugs.

SafeChemo directly addresses these challenges, as it aims at:

• increasing patient safety, 
• lowering operators’ risk of contamination and 
• reducing operating costs.

In order to achieve these goals SafeChemo introduces:

• state of the art automation (robotics and software)
• a thorough validation model to assess the service performance
• reengineering and implementation services 
• maintenance and assistance services

SafeChemo will be market validated in the following test sites:

• The General Hospital of Bolzano in Italy (Google maps link)
• The H:S Pharmacy (part of the Copenhagen University Hospital) in Denmark (Google maps link)
• Imperial College Healthcare NHS Trust London in the United Kingdom (Google maps link)